Key result
Adjuvant and neoadjuvant chemotherapy using anthracycline plus ifosfamide may provide survival benefits for patients with high-risk localized soft tissue sarcomas compared with surgery alone.
Why the study?
Perioperative chemotherapy is a potential treatment option for patients with soft tissue sarcomas at high risk for recurrence or metastasis, but role and efficacy of adjuvant and neoadjuvant regimens warrant discussion.
Does adjuvant or neoadjuvant chemotherapy improve survival in patients with high-risk soft tissue sarcomas compared to surgery alone?
Does adjuvant or neoadjuvant chemotherapy improve survival in patients with high-risk soft tissue sarcomas compared to surgery alone?
Adjuvant and neoadjuvant chemotherapy, particularly anthracycline plus ifosfamide, may offer survival benefits for patients with high-risk soft tissue sarcomas.
Answers are grounded in this paper and cite their sources.
Supports perioperative anthracycline-ifosfamide in high-risk localized STS; strengthens RCT evidence for multimodal therapy.
The standard therapy for all localized soft tissue sarcomas is surgical resection of the tumor. For patients with soft tissue sarcomas who are at high risk for recurrence and/or metastasis, perioperative chemotherapy is a potential treatment option. Adriamycin plus ifosfamide is currently the most promising chemotherapy regimen for localized soft tissue sarcomas. Randomized controlled trials and meta-analyses of adjuvant postoperative chemotherapy for soft tissue sarcomas have suggested that adjuvant chemotherapy may provide an advantage, however small, compared with surgery alone. On the other hand, recent randomized trials have demonstrated the efficacy of neoadjuvant preoperative chemotherapy using full-dose anthracycline plus ifosfamide for high-risk soft tissue sarcomas and showed survival benefits in patients with large, deep-seated and high-grade soft tissue sarcomas of the trunk and extremities. In this review, adjuvant and neoadjuvant chemotherapies for soft tissue sarcomas and future perspectives are discussed.
No takes yet. Share an insight, caveat, or question.
Tanaka et al. (2020) conducted a review in Soft tissue sarcomas. Adjuvant and neoadjuvant chemotherapy vs. Surgery alone was evaluated. Adjuvant and neoadjuvant chemotherapy using anthracycline plus ifosfamide may provide survival benefits for patients with high-risk localized soft tissue sarcomas compared with surgery alone.
Synapse has enriched 10 related papers. Consider them for comparative context: